Regulatory Focus™ > News Articles > 2020 > 5 > FDA tightens oversight of antibody tests for COVID-19

FDA tightens oversight of antibody tests for COVID-19

Posted 04 May 2020 | By Michael Mezher 

FDA tightens oversight of antibody tests for COVID-19

After initially allowing commercial manufacturers and laboratories to market self-validated antibody tests for coronavirus disease (COVID-19), the US Food and Drug Administration (FDA) says that commercial manufacturers must now submit an emergency use authorization (EUA) with validation data to continue marketing the tests.
 
Under its original policy, FDA said it would not object to the development and use of serological tests without FDA review or authorization so long as the tests were validated and the agency had been notified that the company planned to market the tests. More than 100 antibody tests were marketed under the initial policy. (RELATED: FDA cautions antibody test developers against falsely claiming tests are authorized, Regulatory Focus 8 April 2020).
 
The policy change comes after reports emerged questioning the accuracy of some of the tests on the market and an investigation by Democrats on the House Oversight Subcommittee on Economic and Consumer Policy.
 
The revised policy also comes less than a week after FDA issued an umbrella EUA for COVID-19 antibody tests that have undergone independent validation by the National Cancer Institute (NCI) or other government agencies. FDA has now issued EUAs for a dozen antibody tests for COVID-19, with most of the EUAs being granted in the last two weeks, and has received validation data from NCI for 13 test kits.  (RELATED: FDA creates umbrella emergency pathway for COVID-19 serology tests, Regulatory Focus 1 May 2020).
 
“When we issued our original serologic test policy in mid-March, it was critical for the FDA to provide regulatory flexibility for serologic test developers given the nature of this public health emergency and an understanding that the tests were not to be used as the sole basis for COVID-19 diagnosis,” said FDA Commissioner Stephen Hahn.
 
Now, FDA says commercial manufacturers must submit an EUA within 10 business days that includes validation data for the tests and warns that it will publicly disclose the names of companies that fail to do so.
 
In its updated guidance, FDA also provides performance threshold recommendations for specificity and sensitivity for antibody tests as well as voluntary templates for manufacturers and laboratories to follow when submitting EUAs. Hahn said the new templates will help streamline the EUA process for antibody tests.
 
FDA

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe